Extract
As part of the global End TB strategy [1–3], treatment of latent tuberculosis infection (LTBI) is now recommended in low endemic middle- and high-income countries for certain risk groups, such as contacts of pulmonary TB, migrants from high endemic countries and immunocompromised individuals.
Abstract
Completion rate with 12 weeks isoniazid/rifapentine for latent tuberculosis was high. Direct observed therapy was solved with flexibility. Adverse events were mostly mild, except one case of suspected nephrotoxicity, which calls for heightened attention. http://ow.ly/DRE430mw5QQ
Footnotes
Conflict of interest: G. Fröberg has nothing to disclose.
Conflict of interest: L. Jansson has nothing to disclose.
Conflict of interest: J. Bruchfeld has nothing to disclose.
- Received June 15, 2018.
- Accepted October 24, 2018.
- Copyright ©ERS 2019
INDIVIDUALS
Log in using your username and password
LIBRARY USERS
Log in through your institution
Purchase access
CONTACT US
If you have any questions about the ERS publications website, please contact journals@ersnet.org
